AU2023233811A1 - Compositions having improved bioavailability of therapeutics and uses thereof - Google Patents

Compositions having improved bioavailability of therapeutics and uses thereof Download PDF

Info

Publication number
AU2023233811A1
AU2023233811A1 AU2023233811A AU2023233811A AU2023233811A1 AU 2023233811 A1 AU2023233811 A1 AU 2023233811A1 AU 2023233811 A AU2023233811 A AU 2023233811A AU 2023233811 A AU2023233811 A AU 2023233811A AU 2023233811 A1 AU2023233811 A1 AU 2023233811A1
Authority
AU
Australia
Prior art keywords
weight
unsaturated
saturated
mixture
triglycerides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023233811A
Other languages
English (en)
Inventor
Robin M. Bannister
John Brew
Daniel Gooding
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TRx Biosciences Ltd
Original Assignee
TRx Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2022/058180 external-priority patent/WO2022207580A2/en
Application filed by TRx Biosciences Ltd filed Critical TRx Biosciences Ltd
Publication of AU2023233811A1 publication Critical patent/AU2023233811A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2023233811A 2022-03-14 2023-03-14 Compositions having improved bioavailability of therapeutics and uses thereof Pending AU2023233811A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263269330P 2022-03-14 2022-03-14
US63/269,330 2022-03-14
PCT/EP2022/058180 WO2022207580A2 (en) 2021-03-27 2022-03-28 Compositions having improved bioavailability of therapeutics
AUPCT/EP2022/058180 2022-03-28
PCT/EP2023/056506 WO2023174948A2 (en) 2022-03-14 2023-03-14 Compositions having improved bioavailability of therapeutics and uses thereof

Publications (1)

Publication Number Publication Date
AU2023233811A1 true AU2023233811A1 (en) 2024-09-19

Family

ID=85571360

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023233811A Pending AU2023233811A1 (en) 2022-03-14 2023-03-14 Compositions having improved bioavailability of therapeutics and uses thereof

Country Status (7)

Country Link
EP (1) EP4493151A2 (cg-RX-API-DMAC7.html)
JP (1) JP2025509680A (cg-RX-API-DMAC7.html)
AU (1) AU2023233811A1 (cg-RX-API-DMAC7.html)
CA (1) CA3245873A1 (cg-RX-API-DMAC7.html)
IL (1) IL315617A (cg-RX-API-DMAC7.html)
WO (1) WO2023174948A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA202407659B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4784247A1 (en) * 2023-09-28 2026-08-05 The Regents Of The University Of California Methods and compositions of treating age-related conditions
WO2025093572A1 (en) * 2023-10-29 2025-05-08 TRx Biosciences Limited Solid dispersion compositions and uses thereof
WO2026053168A1 (en) * 2024-09-06 2026-03-12 Graviton Bioscience Bv Amorphous forms of a rock2 inhibitor and formulations thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5082667A (en) * 1988-06-07 1992-01-21 Abbott Laboratories Solid pharmaceutical dosage in tablet triturate form and method of producing same
US5885486A (en) * 1993-03-05 1999-03-23 Pharmaciaand Upjohn Ab Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof
US20020028813A1 (en) * 1997-09-03 2002-03-07 Paul F. Jackson Thioalkyl compounds, methods, and compositions for inhibiting parp activity
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
US20060138059A1 (en) 2004-12-28 2006-06-29 Vair Larry L Jr Corona-treated polypropylene liquid filtration media
JP5758630B2 (ja) * 2007-11-15 2015-08-05 エンメエッセディ・イタリア・エッセ・エッレ・エッレ Parp阻害剤としてのピリダジノン誘導体
EP2346495B2 (en) * 2008-10-07 2023-05-24 Kudos Pharmaceuticals Limited Pharmaceutical formulation 514
CN102307576A (zh) * 2008-12-15 2012-01-04 班纳制药公司 用于增强水不溶性活性剂的释放和吸收的方法
CN101507707B (zh) * 2009-04-08 2011-01-19 邓菊娟 一种盐酸法舒地尔脂微球制剂及其制备方法
CN101926757B (zh) * 2010-09-01 2013-01-02 北京大学 一种难溶性药物的液体组合物及其制备方法
CN102813639B (zh) * 2011-06-08 2014-04-30 中国疾病预防控制中心寄生虫病预防控制所 甲苯达唑软胶囊剂
US9073944B2 (en) * 2012-02-21 2015-07-07 Merck Patent Gmbh Cyclic diaminopyrimidine derivatives
AU2014360537B2 (en) * 2013-12-04 2017-09-07 Gilead Sciences, Inc. Methods for treating cancers
ES2975417T3 (es) * 2017-03-03 2024-07-05 Inspirna Inc Formulaciones con estabilidad mejorada
WO2020079706A1 (en) * 2018-10-15 2020-04-23 Cipla Limited Pharmaceutical formulation
WO2020217235A1 (en) * 2019-04-24 2020-10-29 Aizant Drug Research Solutions Private Limited Solid dosage form of dasatinib
CN113546045B (zh) * 2021-08-18 2022-11-11 浙江大学 恢复肿瘤微环境失活树突状细胞功能的纳米制剂及应用

Also Published As

Publication number Publication date
ZA202407659B (en) 2026-01-28
IL315617A (en) 2024-11-01
CA3245873A1 (en) 2023-09-21
EP4493151A2 (en) 2025-01-22
WO2023174948A2 (en) 2023-09-21
WO2023174948A3 (en) 2023-10-26
JP2025509680A (ja) 2025-04-11

Similar Documents

Publication Publication Date Title
EP4493151A2 (en) Compositions having improved bioavailability of therapeutics and uses thereof
Rizvi et al. Simvastatin-loaded solid lipid nanoparticles for enhanced anti-hyperlipidemic activity in hyperlipidemia animal model
Jiang et al. Ionic Liquids: Promising Approach for Oral Drug Delivery: Jiang et al.
CN103002877A (zh) 作为缓解疾病的抗风湿性药(dmard)和抗癌药剂的甲氨蝶呤的持续释放制剂
TW202139984A (zh) 治療性化合物及其調配物與用途
WO2022207580A2 (en) Compositions having improved bioavailability of therapeutics
Shailendrakumar et al. Improved oral pharmacokinetics of pentoxifylline with palm oil and capmul® MCM containing self-nano-emulsifying drug delivery system
Pangeni et al. Improvements in the oral absorption and anticancer efficacy of an oxaliplatin-loaded solid formulation: pharmacokinetic properties in rats and nonhuman primates and the effects of oral metronomic dosing on colorectal cancer
CN101780037B (zh) 双嘧达莫自乳化给药系统及其制备方法
Caliph et al. The impact of lymphatic transport on the systemic disposition of lipophilic drugs
AU2026201779A1 (en) Formulated and/or co-formulated liposome compositions containing IDO antagonist prodrugs useful in the treatment of cancer and methods thereof
JP2026505949A (ja) 自己乳化医薬組成物、その製造方法及び使用
JP2009518443A (ja) 脂質を主材料とする担体に内封された、不溶性小分子治療剤の製剤
CN104224750A (zh) 一种注射用卡巴他赛白蛋白纳米粒制剂及其制备方法
CN105585569A (zh) 一种恩替卡韦脂肪酸衍生物及其药物组合物
US20250195433A1 (en) Compositions Having Improved Bioavailability of Therapeutics and Uses Thereof
KR20210099038A (ko) 시클로스포린 유사체의 제약 제형
Gulyakin et al. Solubilization of hydrophobic antitumor drugs
CN104546722B (zh) 米铂脂质体和制法
KR101859200B1 (ko) 모노아세틸디아실글리세롤 화합물의 경구 투여용 조성물 및 고형 제제
CN101708338B (zh) 含甾体结构的前药及其高度分散制剂
CN111065397A (zh) MEK/PI3K、JAK/MEK、JAK/PI3K/mTOR和MEK/PI3K/mTOR生物学途径的抑制剂和用于改善治疗化合物的淋巴摄取、生物利用度和溶解度的方法
CN104703626B (zh) 用于治疗癌症的基于碘油的抗肿瘤乳剂
US20250195461A1 (en) Fibrate Compositions for Treating Inflammation and Neuroinflammation
Wang et al. Linoleate-pazopanib conjugation as active pharmacological ingredient to abolish hepatocellular carcinoma growth